The use of Benincasa hispida for the treatment of uninvestigated dyspepsia: Preliminary results of a non-randomised open label pilot clinical trial

被引:2
|
作者
Vinaya, T. M. [1 ]
Aravind, B. S. [2 ]
Sibbritt, David [3 ]
Tapasbrata, Tripathy [4 ]
Shivakumar, S. [4 ]
机构
[1] JSS Ayurveda Med Coll, Dept Community Hlth & Prevent Med, Mysore 570028, Karnataka, India
[2] JSS Ayurveda Med Coll, Dept Physiol, Mysore, Karnataka, India
[3] Univ Technol Sydney, Fac Hlth, Ultimo, NSW 2007, Australia
[4] SDM Coll Ayurveda, Dept Community Hlth & Prevent Med, Hassan, Karnataka, India
关键词
Dyspepsia; Benincasa hispida; Ayurveda;
D O I
10.1016/j.aimed.2015.09.003
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Dyspepsia is becoming a common health problem for which an individual seeks medical help. The approach to the management of dyspepsia is complex with high treatment costs and possible adverse effects. Methods: A prospective pilot study was designed to assess the effectiveness of the fruit juice of Ash Gourd (Benincasa hispida) on twenty dyspeptic subjects, who were followed up for 45 days. Measures of retrosternal pain, post-prandial fullness, bloating, sour belching, nausea, vomiting and changes in bowel habits were taken at three times periods (baseline, 30 days and 45 days). Results: Statistically significant improvements were seen in several parameters, including pain (p<0.001), retrosternal burning (p<0.001), nausea (p<0.001),belching(p<0.001) and bowel habits (p<0.05),which are considered as the classical symptoms of dyspepsia. Bloating, though not a common symptom also improved (p<0.001) over time. Conclusion: The trial drug is an effective remedy for uninvestigated dyspepsia. Randomised controlled trials are further needed to confirm the pharmaco-dynamics of the trial drug for anti-ulcer, acid suppression, H-2 receptor antagonistic, anti-cholinergic properties. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:130 / 134
页数:5
相关论文
共 50 条
  • [1] Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole - results from the STARS II study
    van Zanten, S. Veldhuyzen
    Wahlqvist, P.
    Talley, N. J.
    Halling, K.
    Vakil, N.
    Lauritsen, K.
    Flook, N.
    Persson, T.
    Bolling-Sternevald, E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (07) : 714 - 723
  • [2] MICRO-DOSING WITH BUPRENORPHINE TO TRANSFER FROM METHADONE TO BUPRENORPHINE - A NON-RANDOMISED OPEN LABEL CLINICAL TRIAL
    Tremonti, Chris
    Perananthan, Varan
    Buckley, Nicholas
    Blogg, James
    Jamshidi, Nazila
    Haber, Paul S.
    DRUG AND ALCOHOL REVIEW, 2021, 40 : S145 - S145
  • [3] Treatment of Anxiety and Epilepsy With Clobazam: Preliminary Results From an Open Label Clinical Trial
    Salpekar, Jay
    Phelps, Molly
    Bodensteiner, Jennifer
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2019, 31 (03) : E26 - E26
  • [4] Effects of game-based interventions on functional capacity in acutely hospitalised older adults: results of an open-label non-randomised clinical trial
    Cuevas-Lara, Cesar
    Saez de Asteasu, Mikel L.
    Ramirez-Velez, Robinson
    Izquierdo, Mikel
    Zambom-Ferraresi, Fabiola
    Antonanzas-Valencia, Cristina
    Galbete, Arkaitz
    Zambom-Ferraresi, Fabricio
    Martinez-Velilla, Nicolas
    AGE AND AGEING, 2022, 51 (01)
  • [5] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
    Alley, Evan W.
    Lopez, Juanita
    Santoro, Armando
    Morosky, Anne
    Saraf, Sanatan
    Piperdi, Bilal
    van Brummelen, Emilie
    LANCET ONCOLOGY, 2017, 18 (05): : 623 - 630
  • [6] Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial
    Sharma, Arun K.
    Verma, Harish
    Estivariz, Concepcion F.
    Bajracharaya, Luna
    Rai, Ganesh
    Shah, Ganesh
    Sherchand, Jeevan
    Jones, Kathryn A., V
    Mainou, Bernardo A.
    Chavan, Smita
    Jeyaseelan, Vishali
    Sutter, Roland W.
    Shrestha, Laxman P.
    LANCET MICROBE, 2023, 4 (11): : E923 - E930
  • [7] Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial
    Li, Guoming
    Yuan, Mei
    Li, Haihong
    Deng, Changsheng
    Wang, Qi
    Tang, Yexiao
    Zhang, Hongying
    Yu, Weisheng
    Xu, Qin
    Zou, Yuanyuan
    Yuan, Yueming
    Guo, Jiawen
    Jin, Chunming
    Guan, Xiangdong
    Xie, Fengjie
    Song, Jianping
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)
  • [8] Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial
    Yoon, Ho-Kyoung
    Kim, Yong-Ku
    Han, Changsu
    Ko, Young-Hoon
    Lee, Heon-Jeong
    Kwon, Do-Young
    Kim, Leen
    ACTA NEUROPSYCHIATRICA, 2011, 23 (04): : 179 - 183
  • [9] EARLY RESULTS OF BANDED GASTRIC PLICATION VERSUS SLEEVE GASTRECTOMY: A NON-RANDOMISED CLINICAL TRIAL
    Gee, Tikfu
    OBESITY SURGERY, 2013, 23 (06) : 844 - 844
  • [10] Use of itopride in the symptoms of functional dyspepsia in Russia: Results of a Phase IV prospective open-label multicenter clinical trial
    Kasyanenko, V. I.
    Denisov, N. L.
    Vasilyev, Yu. V.
    TERAPEVTICHESKII ARKHIV, 2014, 86 (08) : 35 - 41